Nura Bio
Nura Bio raises $68M Series A at $300M valuation
Nura Bio: Series A Funding Round
Nura Bio has successfully raised $68M in Series A funding, reaching a valuation of $300M.
Company Overview
Biopharmaceutical company developing therapies for neurological diseases
Funding Details
The Series A round was led by Atlas Venture, with participation from Deerfield Management.
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2021
- Employees: 70+
- Category: Biotech
Investment
Nura Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Atlas Venture: Verified investor in Series A
- Deerfield Management: Verified investor in Series A
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free